Vista Pharmaceuticals Management

Management criteria checks 1/4

Vista Pharmaceuticals' CEO is Murali Meraga, appointed in Oct 2022, has a tenure of 1.58 years. directly owns 6.02% of the company’s shares, worth ₹55.77M. The average tenure of the management team and the board of directors is 1.6 years and 6.3 years respectively.

Key information

Murali Meraga

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.6yrs
CEO ownership	6.0%
Management average tenure	1.6yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO

Murali Meraga

1.6yrs

Tenure

Mr. Murali Meraga served as Non-Executive Director of Vista Pharmaceuticals Limited from October 2022 until October 14, 2022 and serves as its Managing Director and Executive Director since October 14, 202...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Suneel Pachipala	Chief Financial Officer	9.1yrs	₹600.00k	no data
Dhananjaya Alli	Chairman and Whole-Time Director of Science & Technology	29.4yrs	no data	4.36% ₹ 40.4m
Murali Meraga	MD & Executive Director	1.6yrs	no data	6.02% ₹ 55.8m
Pavan Gilaka	Whole-Time Director	1.6yrs	no data	6.83% ₹ 63.3m

1.6yrs

Average Tenure

Experienced Management: 524711's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Dhananjaya Alli	Chairman and Whole-Time Director of Science & Technology	29.4yrs	no data	4.36% ₹ 40.4m
Murali Meraga	MD & Executive Director	1.6yrs	no data	6.02% ₹ 55.8m
Pavan Gilaka	Whole-Time Director	1.6yrs	no data	6.83% ₹ 63.3m
Stanley Reddy	Non-Executive Director	7.8yrs	no data	no data
Mallem Rao	Non Executive Director	14.8yrs	no data	0.0021% ₹ 19.6k
Divya Chakravarthula	Non-Executive Independent Director	6.3yrs	no data	no data
Umesh Banakar	Non-Executive Independent Director	6.3yrs	no data	no data
Divakar Yerrabommanahalli	Non Executive Director	4.7yrs	no data	no data
Umakanth Katta	Non Executive Director	3.8yrs	no data	7.55% ₹ 70.0m

6.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 524711's board of directors are considered experienced (6.3 years average tenure).

Vista Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel

Less than half of directors are independent

Less than half of directors are independent

Vista Pharmaceuticals Limited Announces Executive Changes

Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company

Recent updates

New major risk - Market cap size

Vista Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 10, 2024

Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding

New major risk - Shareholder dilution

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Vista Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 12, 2023

Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel

Vista Pharmaceuticals Limited to Report Q4, 2023 Results on May 30, 2023

Vista Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 13, 2023

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Vista Pharmaceuticals Limited Announces Executive Changes

Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company

Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Director

Vista Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2022

Vista Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

Vista Pharmaceuticals Limited Announces Resignation of Akash Bhagadia as Company Secretary and Compliance Officer

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Vista Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 14, 2022

Full year 2021 earnings released: ₹0.63 loss per share (vs ₹1.21 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.13 loss per share (vs ₹0.07 loss in 3Q 2020)

Vista Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 14, 2021

Vista Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2020

New 90-day high: ₹11.40

New 90-day low: ₹8.30

First quarter earnings released

New 90-day low - ₹8.57

Vista Pharmaceuticals Limited to Report Q1, 2021 Results on Sep 14, 2020

New 90-day low - ₹8.90

Vista Pharmaceuticals Limited to Report Q4, 2020 Results on Jun 30, 2020

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age